Epizyme reported $2.64M in Cost of Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbott ABT:US $ 4933M 54M
Agios Pharmaceuticals AGIO:US $ 0.44M 0.1M
Amarin AMRN:US $ 35.81M 13.57M
Amgen AMGN:US $ 1510M 51M
Biogen BIIB:US $ 484M 269.9M
Bluebird Bio BLUE:US $ 1.74M 6.56M
Daiichi Sankyo 4568:JP Y 74798M 14032M
Eisai 4523:JP Y 47404M 3334M
Exelixis EXEL:US $ 13.48M 0.28M
Gilead Sciences GILD:US $ 1442M 18M
GlaxoSmithKline GSK:LN 2136M 1509M
Glaxosmithkline GSK:US $ 2136M 1509M
Karyopharm Therapeutics KPTI:US $ 939K 487K
MacroGenics MGNX:US 2.4M 2.35M
Merk MRK:US $ 3698M 1636M
Novartis NVS:US $ 3749M 6M
Novartis NOVN:VX SF 3749M 6M
Pfizer PFE:US $ 8671M 1339M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Seattle Genetics SGEN:US $ 106.1M 18.47M
Vertex Pharmaceuticals VRTX:US $ 261.8M 16M